Jennifer R Diamond Selected Research

Jennifer R Diamond Research Topics

Disease

35	Neoplasms (Cancer) 01/2022 - 12/2009
20	Triple Negative Breast Neoplasms 06/2022 - 01/2013
14	Breast Neoplasms (Breast Cancer) 06/2021 - 06/2009
6	Ovarian Neoplasms (Ovarian Cancer) 10/2020 - 02/2011
4	Colorectal Neoplasms (Colorectal Cancer) 12/2018 - 06/2010
3	Brain Neoplasms (Brain Tumor) 06/2022 - 07/2014
2	Neutropenia 01/2022 - 01/2017
2	Aneuploidy (Aneuploid) 11/2019 - 10/2018
2	Disease Progression 01/2019 - 01/2018
2	Fatigue 01/2017 - 02/2011
2	Vomiting 01/2017 - 02/2011
2	Nausea 01/2017 - 02/2011
1	T-Cell Lymphoma (Lymphoma, T Cell) 01/2022
1	Anemia 01/2022
1	Hyponatremia 01/2022
1	Non-Hodgkin Lymphoma (Lymphosarcoma) 01/2022
1	Abdominal Pain (Pain, Abdominal) 01/2022
1	Encephalitis (Encephalitis, Rasmussen) 02/2021
1	Limbic Encephalitis (Paraneoplastic Limbic Encephalitis) 02/2021
1	Paraneoplastic Cerebellar Degeneration 02/2021
1	Adenocarcinoma 01/2021
1	Hematologic Neoplasms (Hematological Malignancy) 01/2021
1	Biliary Tract Neoplasms (Biliary Tract Cancer) 01/2021
1	Melanoma (Melanoma, Malignant) 01/2021
1	Body Weight (Weight, Body) 01/2019
1	Uterine Cervical Neoplasms (Cancer of the Cervix) 10/2017
1	Stomatitis 01/2017

Drug/Important Bio-Agent (IBA)

9	Phosphotransferases (Kinase)IBA 01/2021 - 06/2010
8	Biomarkers (Surrogate Marker)IBA 01/2022 - 01/2013
6	ENMD 2076IBA 10/2018 - 06/2010
5	Paclitaxel (Taxol)FDA LinkGeneric 01/2022 - 06/2015
5	Hormones (Hormone)IBA 02/2021 - 03/2020
4	sacituzumab govitecanIBA 06/2022 - 07/2017
4	Immune Checkpoint InhibitorsIBA 01/2021 - 01/2020
4	CateninsIBA 11/2020 - 03/2014
3	atezolizumabIBA 01/2021 - 01/2019
3	Irinotecan (Camptosar)FDA LinkGeneric 01/2021 - 12/2018
3	PlatinumIBA 10/2020 - 02/2011
3	MLN 8237IBA 01/2020 - 05/2015
3	Aurora Kinase AIBA 01/2020 - 06/2010
3	Pharmaceutical PreparationsIBA 06/2015 - 02/2011
2	ErbB Receptors (EGF Receptor)IBA 02/2021 - 07/2014
2	adavosertibIBA 01/2021 - 03/2020
2	Capecitabine (Xeloda)FDA Link 01/2021 - 03/2020
2	sapanisertibIBA 01/2021 - 01/2020
2	RX-5902IBA 11/2020 - 11/2019
2	130-nm albumin-bound paclitaxelIBA 01/2020 - 01/2019
2	Monoclonal AntibodiesIBA 01/2019 - 06/2015
2	Ado-Trastuzumab EmtansineIBA 01/2019 - 07/2014
2	Immunoconjugates (Immunoconjugate)IBA 07/2017 - 03/2016
2	Aurora KinasesIBA 01/2013 - 02/2011
1	taxaneIBA 01/2022
1	Alkaline PhosphataseIBA 01/2022
1	Histone Deacetylases (Histone Deacetylase)IBA 01/2022
1	Histones (Histone)IBA 01/2022
1	Protein Isoforms (Isoforms)IBA 01/2022
1	Cyclin-Dependent Kinase 9IBA 01/2022
1	Histone Deacetylase InhibitorsIBA 01/2022
1	pertuzumabIBA 06/2021
1	Trastuzumab (Herceptin)FDA Link 06/2021
1	neratinibIBA 06/2021
1	human ERBB2 proteinIBA 02/2021
1	AntibodiesIBA 02/2021
1	anti-Yo autoantibodiesIBA 02/2021
1	CytokinesIBA 01/2021
1	Carboplatin (JM8)FDA LinkGeneric 01/2021
1	Fulvestrant (Faslodex)FDA Link 01/2021
1	BenzodiazepinesIBA 01/2021
1	pembrolizumabIBA 01/2021
1	exemestane (Aromasin)FDA Link 01/2021
1	Opioid Analgesics (Opioids)IBA 01/2021
1	Everolimus FDA Link 01/2021
1	AntigensIBA 10/2020
1	AlbuminsIBA 10/2020
1	Mechanistic Target of Rapamycin Complex 1IBA 01/2020
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2019
1	Chemokine CXCL10IBA 01/2019
1	navicixizumabIBA 01/2019
1	B7-H1 AntigenIBA 01/2019
1	Insulin (Novolin)FDA Link 12/2018
1	Insulin ReceptorIBA 12/2018
1	3- (8- amino- 1- (2- phenylquinolin- 7- yl)imidazo(1,5- a)pyrazin- 3- yl)- 1- methylcyclobutanolIBA 12/2018
1	Biological ProductsIBA 01/2018
1	ME-344IBA 10/2017
1	Topoisomerase I InhibitorsIBA 10/2017
1	Topotecan (Hycamtin)FDA LinkGeneric 10/2017
1	PM 01183IBA 01/2017
1	CreatinineIBA 01/2017
1	Transaminases (Aminotransferases)IBA 01/2017
1	Antimitotic AgentsIBA 03/2016
1	MesothelinIBA 03/2016
1	monomethyl auristatin EIBA 03/2016

Therapy/Procedure

12	Therapeutics 06/2022 - 06/2009
7	Drug Therapy (Chemotherapy) 01/2022 - 01/2014
2	Adjuvant Chemotherapy 06/2022 - 01/2022
2	Immunotherapy 01/2021 - 01/2021
1	Oral Administration 01/2022
1	Neoadjuvant Therapy 01/2018
1	Intravenous Infusions 01/2017
1	Aftercare (After-Treatment) 01/2017